Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes

References

Page 1

	Year	Citations
International Diabetes Federation 2017 Ann M. Carracher, Payal H. Marathe, Kelly L. Close Journal of Diabetes	2018	13.5K
Global estimates of the prevalence of diabetes for 2010 and 2030 Jonathan E. Shaw, Richard Sicree, Paul Zimmet Diabetes Research and Clinical Practice ObesityDiabetes EpidemiologyGlobal HealthDiabetesInternational Health	2009	7.2K
Methods for the economic evaluation of health care programmes Sandra Wilson Journal of Epidemiology & Community Health Health EconomicsHealth PolicyOutcomes ResearchHealth Care CostCost Effectiveness	1987	4.3K
Opportunities and responsibilities in pharmaceutical care Charles D. Hepler, Linda M. Strand American Journal of Health-System Pharmacy Drug DispensingAdverse Drug ReactionPrimary CarePharmaceutical PracticeClinical Pharmacy	1990	2.9K
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force Don Husereau, Michael Drummond, Stavros Petrou, Value in Health Health SystemsHealth PolicyHealth Impact AssessmentHealth EconomicsPublic Health	2013	2K
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. A. Laupacis, David Feeny, Allan S. Detsky, PubMed New TechnologyRate Economic EvaluationsProgram EvaluationHealthcare InnovationDigital Health	1992	1.6K
Net Health Benefits Aaron A. Stinnett, John Mullahy Medical Decision Making	1998	1.1K
National Institute for Clinical Excellence and its value judgments M. D. Rawlins, Anthony J. Culyer BMJ Clinical Decision-makingNational InstituteSocial Value JudgmentsClinical SpecialtiesValue Theory	2004	763
The Asheville Project: Long-Term Clinical and Economic Outcomes of a Community Pharmacy Diabetes Care Program Carole W. Cranor, Barry A. Bunting, Dale B. Christensen Journal of the American Pharmaceutical Association (1996) Diabetes ManagementEconomic OutcomesHealth PolicyHealth EconomicsAsheville Project	2003	723
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold Scott D. Grosse Expert Review of Pharmacoeconomics & Outcomes Research Healthcare QualityCost-effectiveness AnalysisHealthcare ValueHealth PolicyHealth Economics	2008	639

Page 1